Schizophrenia.com
AbbVie's VRAYLAR® (cariprazine) Receives Positive Reimbursement Recommendation by Canada's Drug Agency for the Treatment of Schizophrenia
Medications
everhopeful
September 4, 2024, 8:57pm
1
1 Like
Related topics
Topic
Replies
Views
Activity
AbbVie Announces Provincial Reimbursement for VRAYLAR® (cariprazine) for the Treatment of Schizophrenia in Québec
Medications
1
296
April 17, 2023
AbbVie's VRAYLAR® (cariprazine) Now Publicly Reimbursed in Alberta
Medications
1
50
September 15, 2025
VRAYLAR available in pharmacies!
News
15
3095
March 14, 2017
FDA Approves VRAYLAR as Adjunctive Therapy for Major Depressive Disorder and AbbVie Announces Reimbursement Program in Canada
Medications
0
230
June 7, 2023
FDA approves Vraylar / Cariprazine to treat schizophrenia and bipolar disorder
News
43
5991
March 17, 2016